Dermata Therapeutics (NASDAQ:DRMA) versus Editas Medicine (NASDAQ:EDIT) Head to Head Analysis

Editas Medicine (NASDAQ:EDIT) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and target prices for Editas Medicine and Dermata Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1	1	5	0	2.57
Dermata Therapeutics	1	0	1	0	2.00

Editas Medicine currently has a consensus price target of $5.40, suggesting a potential upside of 101.49%. Dermata Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 675.19%. Given Dermata Therapeutics’ higher possible upside, analysts plainly believe Dermata Therapeutics is more favorable than Editas Medicine.

Insider and Institutional Ownership

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 21.9% of Dermata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Editas Medicine and Dermata Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52 million	6.48	-$160.06 million	($1.23)	-2.18
Dermata Therapeutics	N/A	N/A	-$7.56 million	($5.31)	-0.24

Dermata Therapeutics has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Editas Medicine has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Profitability

This table compares Editas Medicine and Dermata Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Dermata Therapeutics	N/A	-127.91%	-105.05%

Summary

Editas Medicine beats Dermata Therapeutics on 7 of the 13 factors compared between the two stocks.

About Editas Medicine

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

About Dermata Therapeutics

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.